These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 28615517)

  • 21. Unravelling the Mechanistic Role of Quinazolinone Pharmacophore in the Inhibitory Activity of Bis-quinazolinone Derivative on Tankyrase-1 in the Treatment of Colorectal Cancer (CRC) and Non-small Cell Lung Cancer (NSCLC): A Computational Approach.
    Okunlola FO; Akawa OB; Subair TI; Omolabi KF; Soliman MES
    Cell Biochem Biophys; 2022 Mar; 80(1):1-10. PubMed ID: 34453681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tankyrase inhibition sensitizes cells to CDK4 blockade.
    Foronda M; Tarumoto Y; Schatoff EM; Leach BI; Diaz BJ; Zimmerman J; Goswami S; Shusterman M; Vakoc CR; Dow LE
    PLoS One; 2019; 14(12):e0226645. PubMed ID: 31891587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance.
    Quackenbush KS; Bagby S; Tai WM; Messersmith WA; Schreiber A; Greene J; Kim J; Wang G; Purkey A; Pitts TM; Nguyen A; Gao D; Blatchford P; Capasso A; Schuller AG; Eckhardt SG; Arcaroli JJ
    Oncotarget; 2016 May; 7(19):28273-85. PubMed ID: 27070088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tankyrase Inhibitors Stimulate the Ability of Tankyrases to Bind Axin and Drive Assembly of β-Catenin Degradation-Competent Axin Puncta.
    Martino-Echarri E; Brocardo MG; Mills KM; Henderson BR
    PLoS One; 2016; 11(3):e0150484. PubMed ID: 26930278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of Novel Inhibitor for WNT/β-Catenin Pathway by Tankyrase 1/2 Structure-Based Virtual Screening.
    Li B; Liang J; Lu F; Zeng G; Zhang J; Ma Y; Liu P; Wang Q; Zhou Q; Chen L
    Molecules; 2020 Apr; 25(7):. PubMed ID: 32268564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Anti-Tumor Activity of Succinyl Macrolactin A Is Mediated through the β-Catenin Destruction Complex via the Suppression of Tankyrase and PI3K/Akt.
    Regmi SC; Park SY; Kim SJ; Banskota S; Shah S; Kim DH; Kim JA
    PLoS One; 2015; 10(11):e0141753. PubMed ID: 26544726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.
    Waaler J; Machon O; Tumova L; Dinh H; Korinek V; Wilson SR; Paulsen JE; Pedersen NM; Eide TJ; Machonova O; Gradl D; Voronkov A; von Kries JP; Krauss S
    Cancer Res; 2012 Jun; 72(11):2822-32. PubMed ID: 22440753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tankyrase is necessary for canonical Wnt signaling during kidney development.
    Karner CM; Merkel CE; Dodge M; Ma Z; Lu J; Chen C; Lum L; Carroll TJ
    Dev Dyn; 2010 Jul; 239(7):2014-23. PubMed ID: 20549720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PI3K and tankyrase inhibitors as therapeutic targets in colorectal cancer.
    Yakkala PA; Naaz F; Shafi S; Kamal A
    Expert Opin Ther Targets; 2024 Mar; 28(3):159-177. PubMed ID: 38497299
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells.
    Bao R; Christova T; Song S; Angers S; Yan X; Attisano L
    PLoS One; 2012; 7(11):e48670. PubMed ID: 23144924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stabilizing and upregulating Axin with tankyrase inhibitor reverses 5-fluorouracil chemoresistance and proliferation by targeting the WNT/caveolin-1 axis in colorectal cancer cells.
    Luo F; Li J; Liu J; Liu K
    Cancer Gene Ther; 2022 Nov; 29(11):1707-1719. PubMed ID: 35750753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models.
    Waaler J; Mygland L; Tveita A; Strand MF; Solberg NT; Olsen PA; Aizenshtadt A; Fauskanger M; Lund K; Brinch SA; Lycke M; Dybing E; Nygaard V; Bøe SL; Heintz KM; Hovig E; Hammarström C; Corthay A; Krauss S
    Commun Biol; 2020 Apr; 3(1):196. PubMed ID: 32332858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tankyrase Inhibition Causes Reversible Intestinal Toxicity in Mice with a Therapeutic Index < 1.
    Zhong Y; Katavolos P; Nguyen T; Lau T; Boggs J; Sambrone A; Kan D; Merchant M; Harstad E; Diaz D; Costa M; Schutten M
    Toxicol Pathol; 2016 Feb; 44(2):267-78. PubMed ID: 26692561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deptor Is a Novel Target of Wnt/β-Catenin/c-Myc and Contributes to Colorectal Cancer Cell Growth.
    Wang Q; Zhou Y; Rychahou P; Harris JW; Zaytseva YY; Liu J; Wang C; Weiss HL; Liu C; Lee EY; Evers BM
    Cancer Res; 2018 Jun; 78(12):3163-3175. PubMed ID: 29666061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical Lead Optimization of a 1,2,4-Triazole Based Tankyrase Inhibitor.
    Waaler J; Leenders RGG; Sowa ST; Alam Brinch S; Lycke M; Nieczypor P; Aertssen S; Murthy S; Galera-Prat A; Damen E; Wegert A; Nazaré M; Lehtiö L; Krauss S
    J Med Chem; 2020 Jul; 63(13):6834-6846. PubMed ID: 32511917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases.
    Lakshmi TV; Bale S; Khurana A; Godugu C
    Curr Drug Targets; 2017; 18(10):1214-1224. PubMed ID: 27425647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. WIKI4, a novel inhibitor of tankyrase and Wnt/ß-catenin signaling.
    James RG; Davidson KC; Bosch KA; Biechele TL; Robin NC; Taylor RJ; Major MB; Camp ND; Fowler K; Martins TJ; Moon RT
    PLoS One; 2012; 7(12):e50457. PubMed ID: 23227175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tankyrase inhibition aggravates kidney injury in the absence of CD2AP.
    Kuusela S; Wang H; Wasik AA; Suleiman H; Lehtonen S
    Cell Death Dis; 2016 Jul; 7(7):e2302. PubMed ID: 27441654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer.
    Gangrade A; Pathak V; Augelli-Szafran CE; Wei HX; Oliver P; Suto M; Buchsbaum DJ
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783777
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
    Shirai F; Tsumura T; Yashiroda Y; Yuki H; Niwa H; Sato S; Chikada T; Koda Y; Washizuka K; Yoshimoto N; Abe M; Onuki T; Mazaki Y; Hirama C; Fukami T; Watanabe H; Honma T; Umehara T; Shirouzu M; Okue M; Kano Y; Watanabe T; Kitamura K; Shitara E; Muramatsu Y; Yoshida H; Mizutani A; Seimiya H; Yoshida M; Koyama H
    J Med Chem; 2019 Apr; 62(7):3407-3427. PubMed ID: 30883102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.